Добавил:
shahzodbeknormurodov27@gmail.com Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Practical Urology ( PDFDrive ).pdf
Скачиваний:
12
Добавлен:
27.08.2022
Размер:
25.91 Mб
Скачать

39

The Management of Testis Cancer

Noel W. Clarke

Presentation and Diagnosis

Testis cancer presents most commonly as a pain­ less testicular mass but there are a number of other clinical scenarios. Approximately 20% manifest with scrotal pain and 10% will initially experience an acute orchitis.1 The primary imag­ ing modality in the first instance is ultrasound.2 This has a sensitivity approaching 100% in expe­ rienced hands but there are circumstances where it is difficult to differentiate orchitis from tumor and in addition, small intratesticular lesions may produce considerable diagnostic uncer­ tainty.Where precise clinical diagnosis is impos­ sible and a lesion is suspicious, open biopsy or orchidectomy may be needed for definitive veri­ fication. If biopsy is to be undertaken, it is usu­ ally done using the Chevassu technique,bivalving the testis along its long axis on the opposite side to the epididymis. In these circumstances, surgi­ cal exploration should always be through the groin and testis conservation should be attemp­ ted where possible. It is inevitable that following surgery some lesions will ultimately prove to be benign: this should be explained to the patient preoperatively.

Serum Tumor Markers

Blood must be taken for marker evaluation before surgical removal of the testis. The main markers for non­seminoma are a fetoprotein

(AFP), b HCG, and LDH. AFP is elevated in 50–70% of NSGCT, has a half­life of approxi­ mately 5 days, and is produced by yolk sac ele­ ments. It is not elevated in pure seminoma. bHCG is increased in 40–60% of NSGCTs and in up to 30% of pure seminomas. It is produced by trophoblastic elements in the tumor and has a half­life of 1 day. LDH is less specific but is more common in seminoma. Overall, 90% of NSGCTs elaborate at least one tumor marker, while in seminoma, markers are elevated in <40%.1

Primary Surgery

It is vital to undertake imaging of the scrotum with ultra sound prior to exploring any scrotal mass, thereby avoiding an inappropriate surgical approach through the scrotum (scrotal violation). If scrotal violation occurs, additional subsequent treatment may be required, often involving local radiotherapy to the scrotal area. This carries the potential for immediate compromise of fertility and a long­standing risk to the endocrine func­ tion of the contralateral testicle.

The standard primary treatment for a testic­ ular tumor is radical orchidectomy. This invo­ lves a groin approach, opening the inguinal canal surgically and detaching the spermatic cord at the level of the internal inguinal ring before delivering the testis from the scrotum and removing the testis and cord en bloc (Fig. 39.1). If the patient wishes, a testicular prosthesis can be inserted safely at the same

C.R. Chapple and W.D. Steers (eds.), Practical Urology: Essential Principles and Practice,

539

DOI: 10.1007/978-1-84882-034-0_39, © Springer-Verlag London Limited 2011

 

540

Practical Urology: EssEntial PrinciPlEs and PracticE

Figure 39.1. radical orchidectomy.

 

suspicious masses should be

b

approached through the groin (a).

 

the inguinal canal is opened and the

 

cord mobilized (b) before transection

 

at the level of the internal ring (c).the

a

testis is then delivered from the

scrotum, dividing the gubernacular

 

attachments (d).

 

c

d

operation, although this should be avoided if the tumor is invading the scrotal wall or if there is preexisting infection.

Testis Preserving Surgery

to surgery and the patient should be counselled about the long­term risks of tumor recurrence, long­term endocrine failure, and the require­ ment for subsequent radiotherapy or comple­ tion orchidectomy if TIN is detected.

This may be undertaken in specific circum­ stances, namely, the presence of synchronous bilateral tumors, development of a metachro­ nous contralateral tumor, or in patients with a single testis. Conservative surgery is usually restricted to tumors of 2 cm or less although it may be possible to undertake local excision of larger tumors provided they are in the polar areas. It should be noted that testicular intraepi­ thelial neoplasia (TIN) is present in up to 80% of patients undergoing testis preservation.3,4 Sperm storage issues should be discussed prior

Contralateral Testicular

Biopsy and TIN

TIN is present in the contralateral testis of up to 5% of men presenting with testicular cancer. When present,it is associated with a high chance of progression to invasive disease. Treatment is usually by low dose irradiation of the affected testis after preliminary storage of semen.

In the case of primary orchidectomy, contro­ versy surrounds the issue of whether synchronous

541

thE ManagEMEnt of tEstis cancEr

contralateral testicular biopsies should be per­

Table 39.1. Egcccg classification for advanced germ cell tumors

formed routinely. Because of this, the policy of

Subgroup

5 year OS

Definition

contralateral biopsy at the time of primary surgery

good

90%

testis or primary

varies. High­risk cases can be identified, limiting

contralateral sampling to those whose risk is great­

prognosis

 

extragonadal retroperito-

 

 

neal tumor and low mar-

est. The combined presence of maldescent, testic­

 

 

 

 

kers afP <1.000 ng/ml,

ular atrophy and age <31 increase the chance of

 

 

 

 

ß-hcg <1.000 ng/ml

positivity for contralateral TIN significantly5 and

 

 

 

 

(<5.000 iU/l) and ldh

such cases should be considered for contralateral

 

 

 

 

<1.5 × normal level and

biopsy. When undertaking biopsies of this type,

 

 

no non-pulmonary

trans­scrotal “pinch” sampling technique should

 

 

visceral metastases

be used, taking a 2–3 mm sample of seminiferous

intermediate

75%

testis or primary extrago-

tissue through a 2–3 mm incision in the scrotum.

prognosis

 

nadal retroperitoneal

Diagnostic accuracy is improved if biopsies are

 

 

 

tumor and intermediate

taken from two separate places in the testis.6

 

 

 

 

markers afP 1.000–

If TIN is identified it should be treated with

 

 

10.000 ng/ml ß-hcg

low dose scrotal radiotherapy. However, this

 

 

1.000–10.000 ng/ml, ldh

treatment can be delayed in order to consider

 

 

1,5–10 × normal level

fertility issues. Prior to treatment, the patient

 

 

and no presence of

needs to be informed that radiotherapy will lead

 

 

non-pulmonary visceral

to irreversible infertility. It is also important to

 

 

metastases

 

 

 

be aware that following radiotherapy to the tes­

Poor

50%

Primary mediastinal germ

tis, even with the standard reduced dose of

prognosis

 

cell tumor or presence

18–20 Gy, about 30% of patients will develop

 

 

of non-pulmonary

Leydig cell insufficiency requiring testosterone

 

 

visceral metastases and/

substitution in the future.

 

 

or“high markers” afP

 

 

 

>10.000 ng/ml, ß-hcg

 

 

 

>10.000 ng/ml ldh >10

Post-Orchidectomy

 

 

× Unl

 

 

 

Management

order lymph nodes in the retroperitoneum are

 

Histological classification and clinical staging is

usually the initial site of metastatic spread

undertaken after primary surgery and subse­

although primary distal hematogenous dissemi­

quent management is predicated on its outcome.

nation can occur in up to 15% of men. CT scan­

The disease stage is classified into two basic

ning has its limitations: up to 30% of patients

groups: clinical stage 1 (low and high risk) and

with negative CT scans will have positive lymph

stage 2 and above, subcategorized into three sub­

nodes detected subsequently at surgical staging.

groups by the European Germ Cell Collaborative

By contrast, up to 25% of patients may be radio­

Consensus Group (EGCCCG) types.7 These sub­

logically overstaged, having abnormal nodes on

classifications are based on the findings of cross­

CT staging, which are subsequently shown to be

sectional imaging and post­orchidectomy tumor

negative following surgical exploration. MR

marker levels. In these more advanced cases

imaging has been used in this scenario although

(clinical stage T2+), defined treatment schedules

it is not proven to be more effective or reliable

are followed according to specific protocols

than CT scanning. PET scanning has significant

predicated on tumor type, marker levels at pre­

problems with false negativity and is of limited

sentation, and the distribution of the disease

utility in this setting. It does have some value in

(Table 39.1).

the post­chemotherapy assessment of the resid­

All patients undergoing orchidectomy must

ual mass in seminoma (see below).

be staged clinically using cross­sectional imag­

Once staging is completed, treatment plans

ing and tumor marker measurement. The imag­

can be formulated, preferably in a multidisci­

ing usually comprises CT scanning of the chest,

plinary forum in a center undertaking manage­

abdomen, and pelvis as a minimum. The first­

ment of testis cancer cases in significant volume.